Atrial fibrillation (AF) is a documented risk factor for dementia. However, it is unclear whether oral anticoagulant (OAC) treatment can reduce the development of dementia or cognitive impairment. We conducted a systematic review and meta-analysis of the association between OAC use and subsequent dementia development in AF patients by searching databases from their inception to February 2018 without language restriction. Six studies (one randomized controlled trial and five observational studies) met the inclusion criteria. The pooled adjusted risk ratios (RRs) suggested a protective effect of OAC use in reducing dementia risk (RR 0.79 [95% CI: 0.67 -0.93], I 2 = 59.7%; P = 0.005). Further, high percentage of time in therapeutic range (TTR) was associated with a decreased risk of dementia (RR 0.38 [95% CI 0.22-0.64], I 2 = 81.8%; P < 0.001). Our results support the hypothesis that AF-related dementia may be due to silent brain infarcts and micro-embolism that could be prevented by OAC use. Future studies with prospective follow-up with direct comparison of vitamin K antagonists and direct oral anticoagulants are needed.
Introduction
Dementia is the development of severe cognitive decline that subsequently causes significant impairment in social and/or occupational functioning (American Psychiatric Association, 2013) . In 2010, it was estimated that 35.6 million people were living with dementia worldwide. It is projected that an excess of 100 million people will have dementia by 2050 (Prince et al., 2013) . The risks of developing dementia increases steadily with increasing age. Its prevalence doubles every 5 years after 65 years of age and incidence also increases exponentially (Hugo and Ganguli, 2014) . People living with dementia have a number of comorbidities which lead to considerable primary care consultations, hospital admissions, and increased risk of death (Browne et al., 2017) . Cardiovascular disease is recognized as a risk factor for developing dementia or cognitive impairment, particularly atrial fibrillation (AF).
A growing body of evidence suggests a relationship between AF and cognitive impairment ranging from mild to severe dementia (Kalantarian et al., 2013; Kwok et al., 2011; Mead and Keir, 2001; Santangeli et al., 2012; Stefanidis et al., 2018) . It is worth noting that AF is associated with a five-fold increased risk of stroke and AF patients with a history of stroke are at a greater risk for an occurrence of dementia or cognitive impairment (January et al., 2014) . In addition, AF and dementia share several cardiovascular risk factors such as https://doi.org/10.1016/j.neubiorev.2018.10.025 Received 10 April 2018; Received in revised form 3 October 2018; Accepted 31 October 2018 hypertension, heart failure, diabetes mellitus, and excessive alcohol intake (Aldrugh et al., 2017) . Therefore, it is not surprising that AF is associated with an increased risk of dementia. However, there was an evidence demonstrating that AF is a risk factor for cognitive decline that occurs independently of ischemic stroke (Bunch et al., 2010; Kalantarian et al., 2013) . Accordingly, additional mechanisms may underlie the association between AF and dementia other than stroke and shared risk factors. One such mechanism is silent cerebral infarct (SCI). A previous systematic review suggested that AF is associated with more than two-fold increase in the odds of developing SCI (Kalantarian et al., 2014) . Therefore, it is hypothesized that effective anticoagulation treatment in patients with AF should preserve cognitive function by reducing infarct burden.
Previous systematic reviews (Cheng et al., 2018; Moffitt et al., 2016 ) have investigated the role of oral anticoagulant (OAC) on the onset of dementia or cognitive impairment, but the results have been conflicting. One study (Moffitt et al., 2016) failed to show any significant reduction in dementia risk, while another study (Cheng et al., 2018) demonstrated an association between OAC use and reduced dementia occurrence. The major limitation of these previous reviews was the inclusion of cross-sectional studies, which could not confirm the temporal relationship between OAC treatment and the development of dementia or cognitive impairment. Accordingly, there is no clear evidence on the direction of effect of anticoagulants in incident dementia. The aim of this systematic review and meta-analysis was to investigate the association between the use of OAC and the incidence of dementia or cognitive impairment in patients with AF.
Methods
This systematic review was conducted in accordance with the principle outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins and Green, 2011) and reported in accordance with the Preferred Reporting Items for Systematic reviews and MetaAnalyses (PRISMA) statement (Moher et al., 2009 
Inclusion and exclusion criteria
The following criteria were used for including studies in our systematic review: (i) randomized controlled trials (RCTs) or observational studies (ii) conducted in patients with AF who were ≥ 18 years and had no history of dementia; (iii) investigated the effects of OACs on the incidence of dementia/cognitive decline; and (iv) reported the outcomes as hazard ratio (HR), risk ratio (RR) or odd ratio (OR), with 95% confidence intervals (CIs). Both vitamin K antagonists (VKAs) and nonvitamin K oral anticoagulants (NOACs) were considered as OACs of interest. Non-OAC users were defined as AF patients who did not receive OAC at study baseline. All studies of any forms of dementia (Alzheimer's/Lew-body/vascular dementia) and cognitive decline were eligible. For studies with overlapping participants, the information with the longest follow-up and the most detailed information were included. The PICOS (Participants, Intervention, Comparators, Outcomes, Study Design) criteria are shown in Supplementary eTable 2.
We excluded studies that were a cross-sectional design (which cannot establish a reliable relationship between OAC use and onset of dementia/cognitive decline), and did not present original data, or were editorials, conference meeting abstracts, expert opinions, case reports, case series, or systematic reviews. Studies that provided only crude RR or unadjusted results may be affected by potential confounding factors and thus were also excluded.
Eligible titles, abstracts and full-text articles were screened by two independent investigators (PM and AN). Any disagreements were resolved through discussion.
Outcome measurement
The primary outcome was the incidence of dementia or cognitive impairment among AF patients with and without OACs. Dementia or cognitive impairment had to be diagnosed based on clinical judgement, results from mental state examinations, cognitive status testing, neuropsychological and physiological testing, established diagnostic criteria for dementia including the Diagnostic and Statistical Manual of Mental Disorders (DSM) -III, DSM-IV, DSM-V, diagnosis based on international classification of diseases codes (ICD), or United Kingdom (UK) Read codes. The secondary outcome was the association between time in therapeutic range (TTR) during warfarin treatment and the risk of dementia. High TTR and low TTR were compared to determine the effect on dementia. We considered high TTR as percentage of TTR ≥ 75% or in quartile 4, and low TTR as TTR ≤ 25% or in quartile 1.
Data extraction and risk of bias assessment
Information were independently extracted from the studies meeting the eligibility criteria by two investigators (PM and AN) using a predesigned data extraction form. The following information was extracted: country of study, study setting, study design, duration of follow-up, sample size, study sample characteristics (age and gender), AF ascertainment, definition of dementia or cognitive impairment, antiplatelet/non-steroidal anti-inflammatory drugs (NSAIDs) use, CHADS 2 or CHA 2 DS 2 -VASc score, OAC used, and comparison group. We also contacted authors when primary outcome data was missing. If the authors did not respond, the study was excluded. Disagreements were resolved by discussion between the two investigators (PM and AN).
Two investigators (PM and AN) independently appraised the risk of bias for the included studies using the Cochrane risk of bias tool for RCTs (Higgins and Green, 2011) . This tool includes seven domains for methodological evaluation: i) sequence generation, ii) allocation concealment, iii) blinding of participants, personnel and outcome assessors, iv) incomplete outcome data, v) selective outcome reporting, and vi) other sources of bias. The RCT was classified as low risk of bias (low risk of bias for all domains), high risk (high risk of bias for one or more domains), or unclear risk (unclear risk of bias for one or more key domains). For observational studies, we used the Newcastle-Ottawa Scale (NOS) (Wells et al., 2014) . Criteria included: selection of the exposed/unexposed cohort, comparability of the study group and the outcome assessment. Studies with a total score of 8 or more were defined as high quality. Any disagreements were resolved by discussion.
Strength of evidence grading
The Grading of Recommended Assessment, Development and Evaluation (GRADE) system, was used to classify the strength of evidence (SOE) based on five key domains; study limitations, directness, consistency, precision, and reporting bias (Berkman et al., 2015) . The ratings classified evidence as high-quality, moderate-quality, lowquality, or insufficient-quality. PM and AN independently evaluated SOE domains for outcomes with different comparisons.
Statistical analysis
The primary analysis compared the incidence of dementia/cognitive impairment between users and non-users of OAC. Results from included studies were expressed as HR, RR, or OR. The RRs were used as the common effect estimates of association across studies. The HRs were considered comparable to RRs (Stare and Maucort-Boulch, 2016.) . However, for studies that provided ORs, a corrected RR was computed using the methods described by (Zhang and Yu, 1998) . We performed meta-analyses under the DerSimonian-Laird random-effects model to pool RR with 95% CIs for the incidence of dementia assuming that the true effect size varied between studies. Homogeneity was assessed using the Cochran Q test, with p < 0.10 (Higgins et al., 2003) . The degree of heterogeneity was estimated by I 2 . I 2 value < 25% indicated low, 25-75% moderate, and > 75% high heterogeneity (Higgins et al., 2003) . To explore possible sources of heterogeneity, subgroup analyses were carried out for different study designs (RCTs versus observational studies), prospective studies versus retrospective studies, and a history of stroke (mixed patients with and without prior stroke versus patients with a prior stroke). Sensitivity analyses were performed by adding unpublished studies and using the 'leave-one-out' approach. A funnel plot was used to investigate any evidence of publication bias, and was statistically assessed by the Begg's and Egger's tests. In addition, the trim-and-fill method was performed to calibrate for publication bias. Statistical tests were two-sided and used a significance threshold of p < 0.05. All analyses were conducted using STATA, v14.1 (StataCorp, Stata Statistical Software. College Station, TX: StataCorp LP; 2015).
Results

Search results
Of the 1926 articles retrieved from electronic databases, 487 were duplicates and 1341 did not meet the eligibility criteria. The remaining 98 full-text articles were evaluated for eligibility. Finally, six studies (Barber et al., 2004; Bunch et al., 2016; Douiri et al., 2013; Friberg and Rosenqvist, 2018; Madhavan et al., 2018; Mavaddat et al., 2014) were included in this systematic review and meta-analysis ( Fig. 1 ).
Study characteristics
Of the six included studies, four (Barber et al., 2004; Bunch et al., 2016; Douiri et al., 2013; Mavaddat et al., 2014) were carried out in the UK, one (Friberg and Rosenqvist, 2018) in Sweden, and one (Madhavan et al., 2018) in the United States. One study (Mavaddat et al., 2014 ) was a RCT, two (Barber et al., 2004; Douiri et al., 2013) were prospective observational studies, and the other two (Friberg and Rosenqvist, 2018; Madhavan et al., 2018) were retrospective observational studies. Of the five included observational studies, one study (Douiri et al., 2013) specifically examined the association of anticoagulant use with dementia in patients with AF who had experienced a stroke. Four studies (Barber et al., 2004; Bunch et al., 2016; Friberg and Rosenqvist, 2018; Madhavan et al., 2018) reported the association in a broader population which included patients both with and without a history of stroke. Only three Madhavan et al., 2018; Mavaddat et al., 2014) studies reported the quality control of warfarin use based on TTR (Supplementary e Table 3 ).
The measurement of dementia or cognitive impairment varied across studies. Two studies (Douiri et al., 2013; Mavaddat et al., 2014) used the Mini-Mental State Examination (MMSE) for cognitive assessment, three studies Friberg and Rosenqvist, 2018; Madhavan et al., 2018) identified dementia using ICD-9 or ICD-10 codes, and one study (Barber et al., 2004) Table 1 .
Based on the quality assessment by NOS, five of the included studies (Barber et al., 2004; Bunch et al., 2016; Douiri et al., 2013; Friberg and Rosenqvist, 2018; Madhavan et al., 2018) were judged as high quality with a score ranging from 8 to 9 (Supplementary eTable 4). One RCT (Mavaddat et al., 2014) was included in the review and it was judged as high risk of bias due to lack of outcome assessment blinding (Supplementary eTable 5). Practitioner recording of MMSE might have influenced treatment allocation. Fig. 2) . Furthermore, five studies (Barber et al., 2004; Douiri et al., 2013; Friberg and Rosenqvist, 2018; Madhavan et al., 2018; Mavaddat et al., 2014) Fig. 2 ). There was one study (Friberg and Rosenqvist, 2018) comparing NOACs to no OAC treatment. The risk of dementia was lower with NOAC treatment (RR 0.40; [95% CI 0.30 -0.54]; P < 0.001).
NOAC use versus VKA use and risk of dementia
One study was included comparing NOACs and VKAs (Friberg and Rosenqvist, 2018) in this systematic review. The results showed that there was no statistically significant difference between the two groups P. Mongkhon et al. Neuroscience and Biobehavioral Reviews 96 (2019) 1-9 Table 1 Characteristics of studies included in the meta-analysis. OACsoral anticoagulants; NOACsnon vitamin K oral anticoagulants; NRnot reported; CIcumulative incidence; ICDInternational Classification of Diseases and Health Related Problems; ECGElectrocardiogram; TTRtime in therapeutic range; IQRinterquartile range, CHADS 2 congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack; CHA 2 DS 2 -VASc congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65-74 years, sex category. a risk of bias was evaluated using The Newcastle-Ottawa Scale (NOS).
brisk of bias was evaluated using Cochrane risk of bias tool for RCTs.
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with respect to the occurrence of dementia (RR 0.97; [95% CI 0.67-1.40]; P = 0.871).
Time in therapeutic range (TTR) and risk of dementia
There were two included studies Madhavan et al., 2018) examining the risk of dementia based on warfarin efficacy. The pooled RR showed that a high percentage of TTR was associated with a significantly decreased risk of dementia (RR 0.38, [95% CI 0.22-0.64], I 2 81.8%; P < 0.001) ( Table 2 , Fig. 3 ).
Subgroup analysis
In subgroup analyses by study design, the pooled RR for observational studies showed a significant association between OAC use and decreased risk of dementia, (RR 0.75 [95% CI: 0.67 -0.83], I 2 = 33.6%; P < 0.001), while RCT results demonstrated no significant association with OAC use (RR 1.31 [95% CI: 0.79-2.18]; P = 0.297). In addition, there was no significant association between OAC use and incidence of dementia in prospective studies and similar results were observed in studies conducted in AF patients with prior stoke (Table 3) .
Sensitivity analysis
After adding unpublished data which was obtained from conference abstracts, the results illustrated that OAC use was not associated with decreased risk of dementia or cognitive impairment. However, there was a trend towards a protective effect with OAC use. The results are shown in supplementary eFig. 1. We also carried out a leave-one-out sensitivity analysis. After the removal of Friberg and Rosenqvist, 2018 and Madhavan et al., 2018, dementia Abbreviations: OAC = oral anticoagulant, VKA = vitamin K antagonist, SOE = strength of evidence, TTR = time in therapeutic range, NA = not applicable, CI = confident interval. displayed in Supplementary eTable 6.
Publication bias
A publication bias assessment using the data of any OAC use and risk of dementia was performed (n = 5 studies). No evidence of publication bias was detected by Begg's test (p = 0.221) and Egger's test (p = 0.219). A well-proportioned funnel plot was formed in a sensitivity analysis using the trim-and-fill method. After the performance of trim-and-fill method, the RR remained unchanged (RR 0.79, 95% CI 0.67 -0.93; P = 0.005). The corresponding funnel plots are displayed in Supplementary eFigure 2-4.
Strength of the body of evidence
Using the GRADE system, we graded the SOE for the association between OAC/VKA treatment and incidence of dementia as low due to moderate study limitations, inconsistency and plausible confounding factors for the included studies. Meanwhile, the comparison between NOAC use and non-OAC use, or direct comparison of NOAC and warfarin and the subsequent of dementia were graded as insufficient because the number of studies were limited. Details of GRADE evidence are shown in Table 2 and Supplementary eTable 7.
Discussion
This systematic review and meta-analysis demonstrated that in patients with AF, oral anticoagulant use was significantly associated with a decreased risk of developing dementia or cognitive impairment by 20% compared with no treatment, but considerable heterogeneity was observed. In addition, in patients using warfarin, an increased TTR correlated with lower risk of dementia. According to GRADE system, the SOE for the association was low or insufficient.
The findings from this study are in line with a recent meta-analysis (Cheng et al., 2018) , which was based on five studies and suggested there was an association between anticoagulant use and reduced incidence of dementia. However, the limitations of previous meta-analysis were the results relied on cross sectional studies, which may introduce bias and confounding, and the effects of VKA alone versus no treatment on dementia were not examined. Furthermore, even though the authors demonstrated a significant association between the use of NOACs versus warfarin and the risk of dementia, one included study reported a composite outcome of stroke/TIA/dementia which reduces the certainty of this result. Our present study provided additional information regarding the association between VKA users and non-VKA users, and included a recently published study (Madhavan et al., 2018) .
Given that OAC reduces the risk of thromboembolism, the findings of this study is supportive of the potential role of subclinical cerebral ischemic lesions in increasing the risk of developing dementia in Fig. 3 . Forest plots showing risk ratio of dementia or cognitive impairment in patients with atrial fibrillation comparing high time in therapeutic range (TTR) and low TTR. Abbreviations: CI = confidence interval; RR = risk ratio; TTR = time in therapeutic range. patients with AF (Gaita et al., 2013; Graff-Radford et al., 2016; Kalantarian et al., 2013) . A high prevalence of silent cerebral ischemia in patients with both paroxysmal and persistent AF has been associated with worse cognitive impairment (Gaita et al., 2013) . Further, there is evidence of elevated markers of hemostatic activation (F1 + 2, TAT, and D-dimer) in patients with AF and dementia compared to those without dementia (Barber et al., 2004) . Moreover, AF is a key risk factor for ischemic stroke (Wolf et al., 1991) . Prior data have demonstrated that the occurrence of stroke in patients with AF was significantly associated with the development of cognitive impairment (RR = 2.7, 95% CI: 1.82-4.00) (Kalantarian et al., 2013) . The absence of OAC was also an independent factor for dementia development in the context of AF (Friberg and Rosenqvist, 2018) . OAC treatment for cardioembolic stroke prevention in AF may confer a decreased risk for the development of dementia or cognitive impairment, which was demonstrated in this meta-analysis. Furthermore, our results suggest that the quality of anticoagulation control with maintaining INRs in the therapeutic range could preserve cognitive function and decrease dementia incidence. This result also supports the hypothesis that chronic cerebral injury or silent cerebral infarct is one of the most likely factors leading to the occurrence of dementia or cognitive impairment in patients with AF. Although this study found a significant association between OAC use and reduced risk of developing dementia or cognitive impairment, several limitations of the included studies are worthy of mention. Firstly, the majority of included studies in the meta-analysis were observational studies. The decision to prescribe OAC was not randomized which could lead to confounding by indication (Salas et al., 1999) . Characteristics of patients who were prescribed OACs may be different from those who were not prescribed OAC in terms of comorbidities and risk of thromboembolic complications. Indeed, it should be noted that individual characteristics including age, the presence of heart failure, hypertension, diabetes, history of stroke and higher CHADS 2 and CHA 2 DS 2 -VASc score, have been associated with increased dementia risk (Duron and Hanon, 2008; Graves et al., 2017; Liao et al., 2015) . Although some studies adjusted for baseline covariates, residual confounders may remain. Secondly, cognitive status of patients might influence clinician decision-making regarding OAC prescribing. Physicians are more likely to prescribe OACs to patients with normal cognitive status (Gussoni et al., 2013) , meanwhile patients with normal cognitive status may be less likely to develop dementia compared to those with cognitive impairment. Therefore, this could overestimate the protective effects of OACs on dementia. Indeed, patients with cognitive impairment may be more likely to go on to develop dementia. Given that non-OAC users are more likely to have worse cognitive function than OAC users at baseline, a more rapid development of dementia in non-OAC users may be observed during study follow-up periods. This is consistent with the study conducted by (Friberg and Rosenqvist, 2018) -of which the results showed a rapid increase of incident dementia among non-users of OAC within the first year of follow-up. Thirdly, cases of early-stage dementia could have gone undetected, which may underestimate the incidence of dementia identified in the studies. Finally, baseline medication use was not obtained across all included studies. NSAIDs or statin have been found to be associated with a reduction in incident dementia de Craen et al., 2005; Swiger et al., 2013) . However, only two studies Friberg and Rosenqvist, 2018) provided these data. Indeed, concomitant medication use might affect the association between OAC use and dementia, as well as lifestyle, genetic and socio-economic factors, which were not adequately examined in the literature available.
For a direct comparison of NOAC and VKA on risk of dementia, it has been proposed that NOAC could preserve the cognitive function better than VKA as they have a lower variability in anticoagulation effect and have a lower risk of intracranial bleeding (Lip et al., 2018; Ruff et al., 2014) . A previous retrospective observational study included in this systematic review showed insignificant results with regards to the risk of dementia. Thus, due to the limited number of studies, we have insufficient evidence to draw a conclusion on which group of oral anticoagulant medication has a better protective effect against dementia. To confirm such a hypothesis, this comparison needs to be investigated with rigorous long-term studies or RCTs. Currently, there are two ongoing RCTs (ClinicalTrials.gov Identifier: NCT01994265 and NCT03061006) that aim to determine the impact of NOACs and VKAs on neurocognitive decline or dementia.
Strengths and limitations
The strengths of this study should be highlighted. First, we applied a comprehensive search strategy without language restriction to ensure that the included studies were representative. Second, the meta-analysis covered updated evidence and reflect real-world practices. In addition, the analyses were performed using rigorous statistical approaches. Finally, our study adheres to the standard methodology of systematic review and meta-analysis as required by the Cochrane and PRISMA checklist (Higgins and Green, 2011; Moher et al., 2009) .
Our study also has limitations. First, it is possible that publication bias exists. Although no evidence of publication bias was found by the Begg's and Egger's test, these methods may be underpowered to detect publication bias due to the small number of included studies. However, after calibration with the trim and fill method, the direction of findings remained unchanged. Second, despite a rigorous and comprehensive search, the majority of included studies in this meta-analysis are observational studies which are prone to bias and unmeasured confounders. On this point, we suggested that the causality of OAC usage and the reduction of dementia cannot be established. Therefore, the results should be interpreted with caution. Third, a moderate degree of heterogeneity may limit our findings. However, we conducted subgroup analyses and found that study design and prior history of stoke/TIA were potential factors contributing to heterogeneity. We conducted a sensitivity analysis where unpublished data from conference abstracts was included. Results demonstrate OAC use was not associated with decreased dementia risk, however a protective trend was apparent. Further, we also conducted sensitivity analyses using the leave-one-out method. Results become statistically non-significant after omitting studies conducted by Friberg and Rosenqvist (2018) and Madhavan et al. (2018) . One explanation for this is that these two studies comprised large cohorts and might have sufficient power to detect an association, and removal of these two studies reduced the statistical power. By contrast, these studies differ from the remaining, as they were retrospective studies. This was also apparent when we did a subgroup analysis by study design which showed that studies of retrospective designs had a significant protective association between OAC use and incidence of dementia. These variable results indicate that a well-designed RCT with a large sample size or sufficiently powered cohort study is needed to help confirm the associations presented in this review. Finally, we found that risk of dementia was lower with NOACs treatment, but no differences were found when comparing NOACs and warfarin. However, this result was based on only a single study, thus, caution should be applied when interpreting this finding.
Implications for practice and future research
This review provides the best available and up-to-date evidence which has implications for clinical decision-making. These findings support the importance of OAC use in AF patients, not only for the prevention of thromboembolic complications, but also for reducing the risk of developing dementia in patients with AF. Physicians should assess the benefits of OAC use and set these against the risks, such as bleeding.
Future directions and improvements to research in the area of the use of OAC in reducing the risk of developing dementia or cognitive impairment could include i) well-designed studies that adjust for confounding factors and include periods of longer follow-up, ii) assess associations between OAC use and dementia/cognitive impairment stratified by age, risk of thromboembolic complications, and medical history, iii) assess the dose-response relationship between the duration of untreated AF and the development of dementia, and iv) assess the benefits of individual OACs, in particular, the NOACs. The effects of these medications on cognitive function still need to be thoroughly investigated.
Conclusions
Oral anticoagulant therapy was associated with a reduced risk of dementia/cognitive impairment in patients with AF. A higher TTR of warfarin treatment had a significant association with decreased risk of dementia compared with patients with lower TTR. However, the results were limited by the lack of adjusted effect ratios and heterogeneity of included studies. More rigorous studies are needed to explore the impact of oral anticoagulant use on dementia.
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